Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has appointed Dennis A. Ausiello, MD, to the company’s Board of Directors. With deep experience and a distinguished record of leadership and accomplishment in medicine and scientific research, Dr. Ausiello brings a seasoned and unique perspective to support Blend’s continued growth and advancement as an innovative oncology drug developer.
“We are privileged to expand our Board of Directors to include Dr. Ausiello, an international leader in academic medicine, with insights in the translation of scientific discoveries to developing new medicines,” said Omid Farohkzad, MD, Founder and Chairman of Blend Therapeutics and Associate Professor at Harvard Medical School. “Denny’s exceptional understanding of how innovative medicines fit into clinical practice will be a tremendous asset to Blend as the company advances a new class of miniaturized biologic drug conjugates with the Pentarin platform and aims to make a significant impact for cancer patients.”